When you have a successful Phase 3 results that are a direct result of financing from NIH, it sure does effect NW Bio "commercializing". NIH loves it when funding money has been used on a successful Phase 3 trial, whether that is a COVID19 vaccine or as in this case, a cancer vaccine. Return on investment. Ands, just incase you somehow missing the the title of the Abstract she will be presenting this coming Sunday.
Autologous tumor lysate-loaded dendritic cell vaccination improves survival in patients with newly diagnosed and recurrent glioblastoma: survival results from a phase 3 trial"
Funny thing, is the real "move" hasnt even happened yet. 16% is a pittance compared to what is going to happen here. Meanwhile, M2Play is spouting nonsense on issues and situations he.she clearly has no idea about. Keep going, I love it.